Viagra Safety Signals & FDA Actions: What Clinicians and Patients Need to Know

How Sildenafil Works: The PDE5 Mechanism

Sildenafil inhibits phosphodiesterase type 5 (PDE5), the enzyme responsible for breaking down cyclic guanosine monophosphate (cGMP) in penile smooth muscle. Sexual stimulation triggers nitric oxide (NO) release from cavernous nerve endings, which activates guanylate cyclase and raises intracellular cGMP. Sildenafil blocks cGMP degradation, sustaining smooth-muscle relaxation, arterial dilation, and the resulting erection. Without sexual stimulation, NO release is minimal and sildenafil has little effect.

The Original Proof-of-Concept Trial

Goldstein et al. Published the landmark Phase III randomized controlled trial in the New England Journal of Medicine in 1998 (N=532 men with erectile dysfunction) [1]. Sildenafil doses of 25 mg, 50 mg, and 100 mg all outperformed placebo on the International Index of Erectile Function (IIEF) erectile-function domain score. At the 100 mg dose, 69% of attempts at sexual intercourse were successful versus 22% with placebo (P<0.001) [1]. That trial formed the core of FDA NDA 020895.

PDE5 Selectivity and Off-Target Effects

Sildenafil is approximately 10-fold more selective for PDE5 over PDE6 (present in retinal photoreceptors), but that residual PDE6 inhibition explains the transient blue-tinge visual disturbance (cyanopsia) reported by roughly 3% of users at the 100 mg dose [1]. At high plasma concentrations, PDE1 inhibition can cause modest systemic vasodilation and a mean 8 to 10 mmHg drop in systolic blood pressure in healthy volunteers [2]. These pharmacodynamic properties underpin most of the safety signals discussed below.

The Nitrate Interaction: The Most Consequential Safety Signal

Concurrent use of sildenafil with any organic nitrate is absolutely contraindicated. Both drug classes lower blood pressure through cGMP-mediated vasodilation; combined, they can produce precipitous, irreversible hypotension and death.

Mechanistic Basis

Organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite) generate NO exogenously, directly stimulating guanylate cyclase and flooding the system with cGMP. When PDE5 is simultaneously blocked by sildenafil, cGMP cannot be cleared. The hemodynamic consequence is additive vasodilation far exceeding either drug alone [3].

Clinical and Regulatory Timeline

The FDA incorporated the nitrate contraindication into the original 1998 label. Post-market case reports of fatal hypotension in men who combined sildenafil with nitroglycerin for chest pain led to repeated label strengthening. The agency's 2002 review of FAERS data identified a disproportionate reporting signal for cardiovascular death in sildenafil users who received emergency nitrates [3]. Current FDA labeling states that sildenafil is contraindicated with all organic nitrates "whether used regularly or intermittently" and with recreational nitrites (poppers) [4].

A 24-hour washout is the minimum window before nitrates may be used after sildenafil; many cardiologists extend this to 48 hours for patients on sildenafil 100 mg given its active metabolite N-desmethylsildenafil [4].

The Riociguat Extension

The FDA expanded contraindicated co-medications in 2013 when riociguat (Adempas), a soluble guanylate cyclase stimulator, received approval for pulmonary arterial hypertension. Combining riociguat with any PDE5 inhibitor, including sildenafil, amplifies cGMP by two complementary mechanisms. The FDA label for riociguat explicitly prohibits co-administration [5].

NAION: The Vision Safety Signal That Reshaped PDE5 Labeling

Non-arteritic ischemic optic neuropathy (NAION) is ischemic injury to the optic nerve head. It causes sudden, painless, permanent vision loss, typically in one eye.

Emergence of the Signal

The first published case series linking sildenafil to NAION appeared in the Journal of Neuro-Ophthalmology in 2005 (Pomeranz and Bhavsar; seven cases) [6]. The FDA received sufficient MedWatch reports to issue a label update in July 2005, adding a specific warning about the risk of NAION in men with a "crowded" optic disc anatomy (small cup-to-disc ratio), prior NAION in the contralateral eye, or cardiovascular risk factors including hypertension, diabetes, hyperlipidemia, and smoking [6].

Epidemiologic Data

A 2006 case-crossover study by McGwin et al. (N=4,000 NAION cases drawn from the Alabama Medicaid database) found an adjusted odds ratio of 2.15 (95% CI 1.06 to 4.36) for sildenafil use in the 24 hours before NAION onset [7]. The absolute risk remains low given the background NAION incidence of roughly 2 to 10 per 100,000 men per year, but the relative signal was sufficient to warrant permanent labeling changes across the entire PDE5 inhibitor class [7].

Current FDA Guidance

The FDA's 2005 and subsequent label revisions direct prescribers to advise patients to stop sildenafil immediately and seek evaluation if sudden vision loss occurs in one or both eyes [4]. Men with a prior NAION episode in one eye are at heightened risk for the fellow eye; the prescribing information recommends a careful risk-benefit discussion before sildenafil is continued or initiated in that population [4].

Sudden Hearing Loss: The 2007 Class-Wide FDA Alert

The Safety Communication

On October 18, 2007, the FDA issued a class-wide drug safety communication requiring all PDE5 inhibitor manufacturers, including Pfizer for Viagra, to add a warning about sudden sensorineural hearing loss (SSNHL) [8]. The signal emerged from spontaneous FAERS reports and published case series describing abrupt unilateral or bilateral hearing loss, sometimes accompanied by tinnitus or vertigo, within hours of PDE5 inhibitor dosing.

Mechanistic Hypothesis

The inner ear cochlea expresses PDE5. Inhibition may alter cochlear blood flow or fluid dynamics, though the exact pathway is not fully established [8]. A 2011 cross-sectional analysis using the National Health and Nutrition Examination Survey (NHANES, N=11,525 adults) found that men who reported ever using PDE5 inhibitors had a statistically higher prevalence of any hearing loss (adjusted OR 1.53, 95% CI 1.11 to 2.11) compared with non-users [9].

Patient Instructions

The current sildenafil label instructs patients to stop the medication immediately and seek prompt medical care if sudden hearing loss, decrease in hearing, or ringing in the ears occurs [4].

Cardiovascular Risk Stratification Before Prescribing

Sildenafil itself does not increase myocardial oxygen demand or exert direct cardiac toxicity. The cardiovascular concern is physiologic: sexual activity raises heart rate and blood pressure, and men with underlying coronary artery disease may experience angina or acute coronary events during intercourse regardless of sildenafil use.

The Princeton Consensus Panels

The Princeton Consensus Conference (three panels: 1999, 2005, and 2012) produced the most widely used clinical framework for risk-stratifying men with cardiovascular disease before PDE5 inhibitor prescribing [10]. The third Princeton Consensus, published in the Mayo Clinic Proceedings in 2012, stratified patients into low, intermediate, and high cardiovascular risk [10].

Low-risk patients (controlled hypertension, mild stable angina, NYHA Class I, II heart failure, post-revascularization without symptoms) may receive sildenafil without additional cardiac evaluation [10].

High-risk patients (unstable angina, recent myocardial infarction within 2 weeks, uncontrolled arrhythmias, NYHA Class III, IV heart failure, severe aortic stenosis) should defer sildenafil until cardiac status is stabilized [10].

Alpha-Blocker Interaction

Men being treated for benign prostatic hyperplasia with alpha-1 blockers (tamsulosin, doxazosin, terazosin) face additive hypotension when sildenafil is co-administered. The FDA label recommends initiating sildenafil at 25 mg in patients stabilized on alpha-blockers, and cautions against simultaneous peak-plasma timing of both agents [4]. Tamsulosin carries the lowest risk among common alpha-blockers because of its uroselectivity, but the interaction is still clinically present.

Priapism: Prolonged Erection and Ischemic Risk

Priapism, defined as an erection lasting more than four hours unrelated to sexual arousal, was present in sildenafil labeling from 1998. Untreated ischemic priapism for six or more hours causes cavernous smooth-muscle necrosis and permanent erectile dysfunction.

Incidence Data

Post-market spontaneous reports to FAERS through 2020 identified priapism as a recurring signal; published estimates suggest an incidence of roughly 1 in 10,000 users, though underreporting is likely [11]. Risk is higher in men with sickle cell disease, leukemia, or multiple myeloma, populations in whom sildenafil is labeled with specific caution [4].

Clinical Management

Current American Urological Association guidelines recommend intracavernous injection of a sympathomimetic agent (phenylephrine preferred; 100 to 500 mcg every 3 to 5 minutes up to 1 hour) as first-line treatment for ischemic priapism of more than 4 hours duration [11]. Surgical shunting is reserved for cases refractory to pharmacologic intervention.

Drug Interactions Beyond Nitrates

CYP3A4 Inhibitors

Sildenafil is metabolized primarily by CYP3A4 and secondarily by CYP2C9. Potent CYP3A4 inhibitors, including ritonavir, ketoconazole, and erythromycin, raise sildenafil plasma concentrations substantially. Ritonavir 500 mg twice daily increased sildenafil AUC 11-fold in a dedicated pharmacokinetic study [4]. The FDA label caps the sildenafil dose at 25 mg every 48 hours in patients receiving ritonavir, and recommends similar caution with other strong CYP3A4 inhibitors [4].

Antihypertensive Agents

Sildenafil produces a mean 8 to 10 mmHg reduction in systolic blood pressure at therapeutic doses. In men concurrently taking amlodipine, this effect is additive but generally modest (additional 8 mmHg systolic reduction in pharmacokinetic studies) and clinically tolerable at standard doses [2]. Combination with multiple antihypertensive classes, however, warrants a 25 mg starting dose to assess tolerability.

Grapefruit Juice

Grapefruit and grapefruit juice inhibit intestinal CYP3A4. A single glass of grapefruit juice raised sildenafil Cmax by approximately 23% in a small pharmacokinetic study [2]; the clinical significance at the 50 mg dose is modest but worth noting in patients who report unusual flushing or hypotension.

FDA Regulatory History: A Timeline of Label Actions

The following chronology synthesizes publicly available FDA regulatory documents and peer-reviewed safety analyses.

March 1998. FDA approves sildenafil citrate (Viagra, Pfizer) via NDA 020895 for erectile dysfunction in adult men [4]. Label includes nitrate contraindication and warnings for priapism and transient visual disturbance from original approval.

2000 to 2002. FDA reviews FAERS data showing post-marketing cardiovascular deaths. Agency concludes that most events occurred in men with pre-existing cardiovascular disease engaging in sexual activity rather than from direct drug toxicity. Label updated to include more detailed cardiovascular prescribing guidance and the Princeton-aligned risk discussion [3].

July 2005. FDA requires Pfizer to add a NAION warning to the Viagra label following spontaneous reports and the Pomeranz case series. The warning was subsequently extended to vardenafil and tadalafil [6].

October 2007. FDA issues a class-wide safety alert requiring all PDE5 inhibitors to add a warning for sudden sensorineural hearing loss, citing post-market reports in FAERS [8].

2013. FDA updates labeling across PDE5 inhibitors to add riociguat as a contraindicated co-medication [5].

2017, present. Multiple generic sildenafil citrate products receive FDA approval. Each generic label mirrors the reference listed drug (Viagra) safety warnings under the Hatch-Waxman framework. The FDA continues to monitor FAERS for emerging signals; no new class-wide safety communications have been issued since 2013 as of the date of this review.

Special Populations and Off-Label Safety Considerations

Pulmonary Arterial Hypertension

The FDA approved sildenafil 20 mg three times daily (marketed as Revatio by Pfizer) for pulmonary arterial hypertension (PAH) in 2005 under a separate NDA. A post-market pediatric study (STARTS-2 long-term extension) raised a safety concern: higher sildenafil doses in children aged 1 to 17 with PAH were associated with increased mortality compared with low doses [12]. The FDA issued a Drug Safety Communication in August 2012 recommending against higher doses in pediatric PAH patients, though the adult PAH indication was unaffected [12].

Women and Off-Label Use

Sildenafil is not FDA-approved for women. Several small randomized trials evaluated sildenafil for female sexual arousal disorder, with inconclusive efficacy results. A Cochrane review published in 2019 (Stephenson and Kerth, 11 trials, N=2,676 women) found no consistent benefit over placebo on validated sexual function scales [13]. The safety profile in women appears similar to men regarding headache, flushing, and hypotension, though the nitrate contraindication applies equally.

Older Adults

Men aged 65 and older have higher sildenafil plasma concentrations due to reduced renal clearance and lower hepatic blood flow. The FDA label recommends initiating at 25 mg in this population [4]. A pharmacokinetic study in men over 65 found a 40% higher mean Cmax compared with men aged 18 to 45 following a single 50 mg dose [2].

Reporting and Monitoring: What Prescribers Should Do

Any suspected adverse drug reaction to sildenafil should be reported through the FDA's MedWatch Safety Reporting Portal (FDA Form 3500A for mandatory healthcare professional reports) [4]. FAERS data are publicly searchable via the FDA's openFDA API, allowing prescribers and researchers to review reported signal counts for any given adverse event term.

Baseline evaluation before prescribing should include blood pressure measurement, medication reconciliation specifically screening for nitrates and alpha-blockers, and a cardiovascular risk assessment using the Princeton framework. Men with optic disc anomalies or a prior NAION episode warrant ophthalmology consultation before sildenafil initiation.

The current sildenafil prescribing information, which incorporates all FDA label changes through the most recent revision, is accessible directly through the FDA's accessdata portal [4].